End Stage Renal Disease (ESRD) Drug Market Report 2025

The end stage renal disease (ESRD) drug market size has grown rapidly in recent years. It will grow from $131.41 billion in 2024 to $149.88 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to increasing incidence of end stage renal disease, growing aging population, improved access to healthcare services, government initiatives and policies, increasing adoption of renal replacement therapies.

The end stage renal disease (ESRD) drug market size is expected to see rapid growth in the next few years. It will grow to $268.44 billion in 2029 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to emerging therapies and drug innovations, increasing healthcare expenditure, rising global burden of chronic kidney diseases, personalized medicine approaches, regulatory support, and expedited approvals. Major trends in the forecast period include increasing incidence of end stage renal disease, advancements in treatment modalities, growing emphasis on precision medicine, development of combination therapies, technological integration in healthcare.

The increasing prevalence of obesity and diabetes is anticipated to drive the growth of the end-stage renal disease (ESRD) drug market in the future. Obesity is characterized by an abnormal or excessive accumulation of fat that poses health risks, while diabetes is a chronic condition that arises when the pancreas fails to produce sufficient insulin or when the body cannot effectively use the insulin it produces. For individuals with renal disease, effectively managing fluid and electrolyte levels, blood pressure, and waste elimination through dialysis can enhance overall health and well-being, potentially leading to weight loss and better blood sugar regulation. For instance, in March 2022, World Obesity, a U.S.-based organization that represents national and regional associations focused on the study and management of obesity, projected that the number of obese individuals would increase to 892 million by 2025 and reach 1.02 billion by 2030. Additionally, in February 2023, the National Health Service, the publicly funded healthcare system in the UK, estimated that the number of people with diabetes in the UK could rise to 5.5 million by 2030, affecting nearly 9% of the population. Consequently, the growing incidences of obesity and diabetes are expected to propel the market for end-stage renal disease (ESRD) drugs.

The rising prevalence of hypertension is projected to drive the growth of the end-stage renal disease (ESRD) drug market in the coming years. Hypertension is a medical condition defined by the long-term force of blood against artery walls that is consistently elevated. ESRD drugs are utilized to manage hypertension by controlling blood pressure, reducing cardiovascular risk, slowing disease progression, and improving fluid balance and quality of life. For example, in December 2023, the Australian Bureau of Statistics, a statutory authority in Australia, reported that 11.6% of the population, or approximately 3 million individuals, had hypertension in 2022. The rates of hypertension were similar for both males and females, at 11.7% and 11.6%, respectively. The prevalence of hypertension increased with age, nearly tripling from 4.7% in the 35-44 age group to 12.4% in the 45-54 age group. This trend continued, with nearly half (45.2%) of individuals aged 75 and older reporting hypertension. Therefore, the growing prevalence of hypertension is fueling the expansion of the end-stage renal disease (ESRD) drug market.

Innovative product development emerges as a prominent trend shaping the end-stage renal disease (ESRD) drug market landscape. Leading companies within this sector are prioritizing the development of innovative solutions to bolster their market positions. A notable instance occurred in April 2022 when GlaxoSmithKline Plc, a UK-based pharmaceutical and biotechnology firm, announced the acceptance of the New Drug Application (NDA) for daprodustat by the US Food and Drug Administration (FDA). Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is aimed at potentially treating chronic kidney disease anaemia (CKD). This product is founded on groundbreaking science that elucidated cellular oxygen sensing and adaptation, marking a milestone in novel therapeutic approaches within the ESRD drug market.

Prominent companies in the end-stage renal disease (ESRD) drug market are strategically focusing on securing product approvals, exemplified by Jardiance, to augment their market revenues. Jardiance, featuring empagliflozin, is tailored to aid individuals diagnosed with type 2 diabetes and reduce the risk of cardiovascular complications in those with type 2 diabetes experiencing heart failure or cardiovascular disease. A significant development occurred in September 2023 when Boehringer Ingelheim Pharmaceuticals Inc., a US-based pharmaceutical company, obtained FDA approval for Jardiance. This drug has received approval for various indications, including reducing the risk of end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease prone to progression. Additionally, it aims to diminish the risk of sustained decline in estimated glomerular filtration rate (eGFR) in adults suffering from heart failure. Notably, Jardiance operates as a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with contraindications for patients with type 1 diabetes and those exhibiting an eGFR lower than 20 ml/min/1.73 m.

In August 2022, Gore & Associates, a materials science company based in the U.S., acquired InnAVasc Medical Inc. for an undisclosed sum. This acquisition enhances Gore’s range of dialysis access solutions by integrating InnAVasc’s innovative graft technology. The InnAVasc device is designed to offer safer, easier, and more reliable access for dialysis patients utilizing graft circuits, ultimately supporting better treatment outcomes. InnAVasc Medical Inc. specializes in medical technology aimed at improving care for patients with end-stage renal disease.

Major companies operating in the end stage renal disease (ESRD) drug market include Pfizer Inc., AstraZeneca plc, Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, Bristol-Myers Squibb Company, B. Braun SE, Asahi Kasei Medical Co. Ltd., Nikkiso Co. Ltd., Abbott Laboratories, Merck Co. & KGaA.

North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (esrd) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the end stage renal disease (esrd) drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

End Stage Renal Disease (ESRD) drugs are medications employed in the treatment of a medical condition wherein a person's kidneys permanently cease to function, necessitating either a kidney transplant or a regular and long-term dialysis regimen to sustain life. These drugs play a crucial role in addressing and preventing secondary complications in individuals suffering from chronic renal disease (CKD).

The main categories of End Stage Renal Disease (ESRD) drugs include calcimimetics, vitamin D, sterols, potassium binders, calcium-based phosphate binders, and others. Calcimimetics are used to reduce parathyroid hormone (PTH) levels in kidney disease stage 5D, with their application dependent on serum calcium and phosphorus levels. Various indications for these drugs include ESRD-induced hyperparathyroidism, hyperphosphatemia, and hyperkalemia. End Stage Renal Disease drugs are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, catering to usage in hospitals, homecare settings, specialty clinics, and other end-user environments.

The end stage renal disease (ESRD) drug market research report is one of a series of new reports that provides end stage renal disease (ESRD) drug market statistics, including end stage renal disease (ESRD) drug industry global market size, regional shares, competitors with an end stage renal disease (ESRD) drug market share, detailed end stage renal disease (ESRD) drug market segments, market trends and opportunities, and any further data you may need to thrive in the end stage renal disease (ESRD) drug industry. This end stage renal disease (ESRD) drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The end-stage renal disease (ESRD) drug market consists of sales of cinacalcet hcl, diuretics, sevelamer, epoetin alfa, and over-the-counter drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.